The most trusted news from Denmark
Provided by AGPCOPENHAGEN, Denmark, April 14, 2026 (GLOBE NEWSWIRE) -- Arla Foods Ingredients has developed high-protein, nutrient-dense application concepts for users of GLP-1 anti-obesity medications, which it will showcase at Vitafoods Europe (5th-7th May 2026 in Barcelona).
Originally developed to treat diabetes, GLP-1 receptor agonists have re-shaped the weight management market. In 2025, 11% of consumers globally [1] and 18% in the US [2] who were actively trying to lose weight reported using them, with uptake expected to rise as availability expands, tablet formats emerge and prices fall [3].
However, GLP-1 use is associated with side effects: lean muscle loss may reach 40% of total mass lost, versus around 25% with traditional interventions [4, 5, 6], while up to 76% of GLP-1 consumers report gastric discomfort and reduced appetite [7].
To help manufacturers address these needs, Arla Foods Ingredients has developed high-protein concepts with Nutrilac® and Lacprodan® BLG-100, delivering all essential amino acids for muscle health in nutrient-dense formats, and incorporating probiotics / cultures from Novonesis to support digestive well-being.
The range includes great-tasting formats for reduced appetites:
Anne Widart, Chief Commercial Officer of Arla Foods Ingredients, said: “Nutrition for GLP-1 users is a growing category, creating opportunities for dairy manufacturers. There is increasing demand for nutrient-dense, high-protein products in formats suited to smaller appetites. Our concepts are designed to help manufacturers respond to these evolving needs.”
Arla Foods Ingredients will showcase the GLP-1 companion nutrition solutions at Vitafoods Europe (Stand #3G156) alongside two additional concepts:
Photo https://www.globenewswire.com/NewsRoom/AttachmentNg/debb0da5-3fc7-43ee-93f7-b975d7eab6b0

Media contact: hz@ispiderpr.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.